The role of complement in kidney disease

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F23%3A00084359" target="_blank" >RIV/00023001:_____/23:00084359 - isvavai.cz</a>

Výsledek na webu

<a href="https://www.nature.com/articles/s41581-023-00766-1" target="_blank" >https://www.nature.com/articles/s41581-023-00766-1</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1038/s41581-023-00766-1" target="_blank" >10.1038/s41581-023-00766-1</a>

Jazyk výsledku

angličtina

Název v původním jazyce

The role of complement in kidney disease

Popis výsledku v původním jazyce

The complement cascade comprises soluble and cell surface proteins and is an important arm of the innate immune system. Once activated, the complement system rapidly generates large quantities of protein fragments that are potent mediators of inflammatory, vasoactive and metabolic responses. Although complement is crucial to host defence and homeostasis, its inappropriate or uncontrolled activation can also drive tissue injury. For example, the complement system has been known for more than 50 years to be activated by glomerular immune complexes and to contribute to autoimmune kidney disease. Notably, the latest research shows that complement is also activated in kidney diseases that are not traditionally thought of as immune-mediated, including haemolytic-uraemic syndrome, diabetic kidney disease and focal segmental glomerulosclerosis. Several complement-targeted drugs have been approved for the treatment of kidney disease, and additional anti-complement agents are being investigated in clinical trials. These drugs are categorically different from other immunosuppressive agents and target pathological processes that are not effectively inhibited by other classes of immunosuppressants. The development of these new drugs might therefore have considerable benefits in the treatment of kidney disease. The complement system is often involved in immune-driven kidney injury. In this Review, the authors discuss complement activation in a variety of kidney diseases, including conditions not traditionally considered to be immune-mediated, and the potential of complement therapeutics for the treatment of kidney disease. The complement system is activated in kidney diseases of different aetiologies, including diseases involving immune complex formation, thrombotic microangiopathy, C3 glomerulopathy, glomerulosclerosis and acute kidney injury.Experimental and clinical evidence suggests that the complement cascade contributes to injury in diseases that are not traditionally regarded as immune mediated, including diabetic kidney disease and focal segmental glomerulosclerosis.The mechanisms of complement activation, including the activation pathways involved, vary among different kidney diseases, as do their downstream pathological effects.Deposition of immune complexes in the glomerular capillaries, the high local concentration of complement proteins and the delicate system of complement regulation within the kidney might all contribute to its unique susceptibility to complement-mediated injury.Many complement-inhibiting drugs have been approved, and additional agents targeting different components along the complement cascade are being investigated in clinical trials.Complement-inhibiting drugs target immune system pathways that are not directly blocked by other immunosuppressive agents.

Název v anglickém jazyce

The role of complement in kidney disease

Popis výsledku anglicky

The complement cascade comprises soluble and cell surface proteins and is an important arm of the innate immune system. Once activated, the complement system rapidly generates large quantities of protein fragments that are potent mediators of inflammatory, vasoactive and metabolic responses. Although complement is crucial to host defence and homeostasis, its inappropriate or uncontrolled activation can also drive tissue injury. For example, the complement system has been known for more than 50 years to be activated by glomerular immune complexes and to contribute to autoimmune kidney disease. Notably, the latest research shows that complement is also activated in kidney diseases that are not traditionally thought of as immune-mediated, including haemolytic-uraemic syndrome, diabetic kidney disease and focal segmental glomerulosclerosis. Several complement-targeted drugs have been approved for the treatment of kidney disease, and additional anti-complement agents are being investigated in clinical trials. These drugs are categorically different from other immunosuppressive agents and target pathological processes that are not effectively inhibited by other classes of immunosuppressants. The development of these new drugs might therefore have considerable benefits in the treatment of kidney disease. The complement system is often involved in immune-driven kidney injury. In this Review, the authors discuss complement activation in a variety of kidney diseases, including conditions not traditionally considered to be immune-mediated, and the potential of complement therapeutics for the treatment of kidney disease. The complement system is activated in kidney diseases of different aetiologies, including diseases involving immune complex formation, thrombotic microangiopathy, C3 glomerulopathy, glomerulosclerosis and acute kidney injury.Experimental and clinical evidence suggests that the complement cascade contributes to injury in diseases that are not traditionally regarded as immune mediated, including diabetic kidney disease and focal segmental glomerulosclerosis.The mechanisms of complement activation, including the activation pathways involved, vary among different kidney diseases, as do their downstream pathological effects.Deposition of immune complexes in the glomerular capillaries, the high local concentration of complement proteins and the delicate system of complement regulation within the kidney might all contribute to its unique susceptibility to complement-mediated injury.Many complement-inhibiting drugs have been approved, and additional agents targeting different components along the complement cascade are being investigated in clinical trials.Complement-inhibiting drugs target immune system pathways that are not directly blocked by other immunosuppressive agents.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30217 - Urology and nephrology

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2023

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Nature Reviews Nephrology

ISSN

1759-5061

e-ISSN

1759-507X

Svazek periodika

19

Číslo periodika v rámci svazku

12

Stát vydavatele periodika

DE - Spolková republika Německo

Počet stran výsledku

17

Strana od-do

771-787

Kód UT WoS článku

001071106200002

EID výsledku v databázi Scopus

2-s2.0-85171889254